Life science companies face unique financial and operational hurdles that require specialized experience. Extended development cycles can stretch 10-15 years with uncertain outcomes. Clinical trials require significant upfront investment with no immediate revenue. Regulatory compliance demands sophisticated financial reporting. Resource allocation decisions happen under extreme uncertainty, making it critical to allocate limited resources to high-value drug development programs.
Our team partners with founders, CEOs, boards, and investors to guide emerging and mid-sized companies through periods of growth and transition. We help businesses in sectors like diagnostics, pharmaceuticals, therapeutics, and medical devices navigate complex situations including M&A transactions, rapid growth and turnarounds.
How we help Life Sciences companies
Clinical operations: We help build relationships with external vendors, such as study investigators, CROs, and central labs, to maximize trial efficiency.
Go to market: We prepare you for commercial launch, including implementing ERP systems, establishing a chain of custody, and structuring financial statements.
Strategic planning: In today’s challenging environment, it’s critical to allocate limited resources to high-value drug development programs. We help you make those strategic decisions.
FP&A: Our focus is on multi-year planning that accounts for extended drug development life cycles.
Cash flow: We use scenario planning to manage limited cash flows and leverage clinical milestones to secure advantageous funding opportunities.
Financial support: We build strong relationships with your functional leads, C-suite, board members, and investors to support critical decisions, from internal hiring to external business development opportunities.
Interim CFO: We can serve as your interim CFO during a transition, working with your finance, accounting, and operations teams to ensure a seamless shift.
